Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Connect Biopharma Holdings Limited American Depositary Shares
CNTB | US
2.15
USD-0.19
-8.12%
CNTB | US
About Connect Biopharma Holdings Limited American Depositary Shares
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
2.15
Open
2.34
High
2.36
Low
2.15
Connect Biopharma Holdings Limited a clinical-stage biopharmaceutical company focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201 an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307 a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174 a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego California.
View LessCNTB | US
Risk
84.3
Sharpe
1.43
Luna's Score
52/100
Recommendation
Hold
Luna says (CNTB | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
78.4%1 month
84.3%3 months
87.6%6 months
85.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
0.77
Price to book
0.62
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
0.19
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-24.95M
MarketCap
118.80M
MarketCap(USD)
118.80M
Div. yield
-
Op. margin
24.64
Erngs. growth
-
Rev. growth
-
Ret. on equity
-17.92
Short ratio
1.17
Short perc.
0.12
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.57
Range1M
0.57
Range3M
1.67
Volumes: Market Activity
Rel. volume
1.29
Price X volume
486.79K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.19 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.62 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 87.62 | - | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 118.80M | - | Emerging |
